An integrated approach to diabetic retinopathy research

Archives of Ophthalmology

Volumn 129, Issue 2, 2011, Pages 230-235

  Gardner, Thomas W ^a   Abcouwer, Steven F ^a   Barber, Alistair J ^a   Jackson, Gregory R ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN RECEPTOR;

DIABETIC RETINOPATHY; HUMAN; INSULIN DEFICIENCY; INSULIN PUMP; LASER COAGULATION; MEDICAL RESEARCH; METABOLIC REGULATION; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA INJURY; REVIEW; VISUAL ACUITY; VISUAL IMPAIRMENT;

BIOMEDICAL RESEARCH; DIABETES MELLITUS; DIABETIC RETINOPATHY; HUMANS; RECEPTOR, INSULIN; RETINA;

EID: 79951643170     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.362     Document Type: Review

References (45)

1. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.
2. Wilkinson-Berka JL, Miller AG. Update on the treatment of diabetic retinopathy. Scientific World Journal. 2008;8:98-120. (Pubitemid 351270286)
3. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30(2):65-84.
4. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009;15(11):1298-1306.
5. Wolter JR. Diabetic retinopathy. Am J Ophthalmol. 1961;51:1123-1141.
6. Bloodworth JMB Jr. Diabetic retinopathy. Diabetes. 1962;11:1-22.
7. Antonetti DA, Barber AJ, Bronson SK, et al; JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55(9):2401-2411. (Pubitemid 44871140)
8. Masland RH. The fundamental plan of the retina. Nat Neurosci. 2001;4(9):877-886. (Pubitemid 32801590)
9. Caputo S, Di Leo MA, Falsini B, et al. Evidence for early impairment of macular function with pattern ERG in type I diabetic patients. Diabetes Care. 1990;13(4):412-418. (Pubitemid 20109477)
10. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999;40(11):2638-2651. (Pubitemid 29455495)
11. Daley ML, Watzke RC, Riddle MC. Early loss of blue-sensitive color vision in patients with type I diabetes. Diabetes Care. 1987;10(6):777-781. (Pubitemid 18049836)
12. Lopes de Faria JM, Katsumi O, Cagliero E, Nathan D, Hirose T. Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus. Graefes Arch Clin Exp Ophthalmol. 2001;239(9):643-648. (Pubitemid 32927012)
13. Ng JS, Bearse MA Jr, Schneck ME, Barez S, Adams AJ. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci. 2008;49(4):1622-1628.
14. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126(2):227-232. (Pubitemid 351240852)
15. Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46(6):2210-2218.
16. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102(4):783-791. (Pubitemid 28399611)
17. Rungger-Brändle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;41(7):1971-1980. (Pubitemid 30354375)
18. Barber AJ, Antonetti DA, Gardner TW; The Penn State Retina Research Group. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. Invest Ophthalmol Vis Sci. 2000;41(11):3561-3568.
19. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54(5):1559-1565. (Pubitemid 40586690)
20. Lieth E, Barber AJ, Xu B, et al; Penn State Retina Research Group. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes. 1998;47(5):815-820. (Pubitemid 28201813)
21. Gastinger MJ, Barber AJ, Khin SA, McRill CS, Gardner TW, Marshak DW. Abnormal centrifugal axons in streptozotocin-diabetic rat retinas. Invest Ophthalmol Vis Sci. 2001;42(11):2679-2685. (Pubitemid 32954880)
22. Gastinger MJ, Singh RS, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci. 2006;47(7):3143-3150. (Pubitemid 351639794)
23. Gastinger MJ, Kunselman AR, Conboy EE, Bronson SK, Barber AJ. Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Invest Ophthalmol Vis Sci. 2008;49(6):2635-2642.
24. VanGuilder HD, Brucklacher RM, Patel K, Ellis RW, Freeman WM, Barber AJ. Diabetes downregulates presynaptic proteins and reduces basal synapsin I phosphorylation in rat retina. Eur J Neurosci. 2008;28(1):1-11.
25. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999;96(19):10836-10841. (Pubitemid 29442230)
26. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW; Penn State Retina Research Group. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes. 1998;47(12):1953-1959. (Pubitemid 28549205)
27. Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis. 2007;10(2):103-117. (Pubitemid 46440630)
28. Tavakoli M, Kallinikos PA, Efron N, Boulton AJ, Malik RA. Corneal sensitivity is reduced and relates to the severity of neuropathy in patients with diabetes. Diabetes Care. 2007;30(7):1895-1897. (Pubitemid 47036377)
29. Bliss M. The Discovery of Insulin. Chicago, IL: University of Chicago Press; 1982.
30. Reiter CE, Sandirasegarane L, Wolpert EB, et al. Characterization of insulin signaling in rat retina in vivo and ex vivo.AmJ Physiol Endocrinol Metab. 2003;285(4):E763-E774. (Pubitemid 37176427)
31. Reiter CEN, Wu X, Sandirasegarane L, et al. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes. 2006;55(4):1148-1156. (Pubitemid 44100194)
32. Rajala RV, Wiskur B, Tanito M, Callegan M, Rajala A. Diabetes reduces autophosphorylation of retinal insulin receptor and increases proteintyrosine phosphatase-1B activity. Invest Ophthalmol Vis Sci. 2009;50(3):1033-1040.
33. Kondo T, Kahn CR. Altered insulin signaling in retinal tissue in diabetic states. J Biol Chem. 2004;279(36):37997-38006. (Pubitemid 39195515)
34. Fox TE, Han X, Kelly S, et al. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes. 2006;55(12):3573-3580. (Pubitemid 44923619)
35. Tikhonenko M, Lydic TA, Wang Y, et al. Remodeling of retinal fatty acids in an animal model of diabetes: a decrease in long-chain polyunsaturated fatty acids is associated with a decrease in fatty acid elongases Elovl2 and Elovl4. Diabetes. 2010;59(1):219-227.
36. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
37. Greenstein VC, Holopigian K, Hood DC, Seiple W, Carr RE. The nature and extent of retinal dysfunction associated with diabetic macular edema. Invest Ophthalmol Vis Sci. 2000;41(11):3643-3654.
38. Ghirlanda G, Di Leo MA, Caputo S, Cercone S, Greco AV. From functional to microvascular abnormalities in early diabetic retinopathy. Diabetes Metab Rev. 1997;13(1):15-35. (Pubitemid 27213791)
39. Spry PG, Johnson CA, Mansberger SL, Cioffi GA. Psychophysical investigation of ganglion cell loss in early glaucoma. J Glaucoma. 2005;14(1):11-19. (Pubitemid 40165486)
40. van Dijk HW, Kok PH, Garvin M, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50(7):3404-3409.
41. van Dijk HW, Verbraak FD, Kok PH, et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51(7):3660-3665.
42. Cunha-Vaz J. Characterization and relevance of different diabetic retinopathy phenotypes. Dev Ophthalmol. 2007;39:13-30.
43. Gardner TW, Jackson GR, Quillen DA, Scott IU. Diabetic retinopathy: translating discoveries to treatments. In: Greenbaum C, Harrison LC, eds. Diabetes: Translating Discoveries into Practice. New York, NY: Informa Press; 2008.
44. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol. 2008;126(12):1740-1747.
45. Csaky KG, Richman EA, Ferris FL III. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2008;49(2):479-489.